Current Report Filing (8-k)
21 June 2017 - 1:45AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________
FORM 8-K
____________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): June 19, 2017
____________________________
XBIOTECH INC.
|
(Exact name of Registrant as specified in its charter)
|
____________________________
British Columbia, Canada
|
(State of Incorporation)
|
|
|
001-37347
|
(Commission File Number)
N/A
|
(I.R.S. Employer Identification No.)
|
8201 E Riverside Dr. Bldg 4, Ste 100
Austin, Texas
(Address of principal executive offices)
|
78744
(Zip Code)
|
(512) 386-2900
(Registrant’s telephone number, including
area code)
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter)
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
The annual meeting of the stockholders
of XBiotech Inc. (the “Company”) was held on June 19, 2017. The matters that were voted upon at the meeting, and the
number of votes cast for and against, as well as the number of abstentions and broker non-votes as to each such matter are set
forth below. Stockholders voted in accordance with the Board of Directors’ recommendations on each matter and voted to (1)
elect four nominees for director; and (2) ratify the selection by the Audit Committee of the Board of Directors of Ernst &
Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending 2017.
Proposal #1
Election of four members of the Board
of Directors
|
For
|
Abstain
|
Broker Non-Votes
|
John Simard
|
11,425,514
|
9,820
|
1,942,756
|
Dr. Fabrizio Bonanni
|
11,403,204
|
32,130
|
1,942,756
|
W. Thorpe McKenzie
|
11,162,955
|
272,379
|
1,942,756
|
Dr. Daniel Vasella
|
11,404,451
|
30,883
|
1,942,756
|
Proposal #2
Ratification of the selection of Ernst
& Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending 2017
For
|
Against
|
Abstain
|
Broker Non-Votes
|
13,224,828
|
65,355
|
87,907
|
0
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: June 20, 2017
|
XBIOTECH INC.
|
|
|
|
|
|
|
|
By:
|
/s/John Simard
|
|
|
John Simard
|
|
|
Chief Executive Officer and President
|
XBiotech (NASDAQ:XBIT)
Historical Stock Chart
From Mar 2024 to Apr 2024
XBiotech (NASDAQ:XBIT)
Historical Stock Chart
From Apr 2023 to Apr 2024